Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

NSCLC 1

Interventions

Pemetrexed 3Carboplatin 3HM781-36B 2Gemcitabine 2pembrolizumab 1osimertinib 1aumolertinib 1aflutinib 1Taxes 1Paclitaxel 1Erlotinib Hydrochloride 1Clinical Trials, Phase I as Topic 1Cisplatin 1Bortezomib 1BID protein, human 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NSCLC × aumolertinib × Clear all
NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡